Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PROK
PROK logo

PROK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Prokidney Corp (PROK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.950
1 Day change
-2.01%
52 Week Range
7.130
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PROK is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows some near-term technical improvement, but the broader setup is weak: no AI Stock Picker or SwingMax buy signal, insiders are selling aggressively, hedge funds are neutral, there is no recent news catalyst, and the options market is extremely thin while implied volatility is very high. With no strong fundamental update and a negative near-term trend estimate, this is not an attractive immediate buy.

Technical Analysis

Price closed at 2.00, just below the prior close of 2.03. Short-term momentum is mixed to mildly positive: MACD histogram is above zero and expanding, but RSI at 66.97 is near the upper neutral/borderline overbought zone, and moving averages are converging rather than showing a strong breakout trend. Key levels: pivot 1.912, resistance 2.143 and 2.286, support 1.681 and 1.538. The stock is trading near the pivot but has not confirmed a strong uptrend. The pattern-based outlook is weak, with estimated next-day, next-week, and next-month performance all negative on average.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper because the put-call ratio is extremely low, but the market is very thin: call open interest is 11,452 versus put open interest of 649, and today’s option volume is only 32 contracts. Implied volatility is very high at 209.67, suggesting expensive options and uncertain pricing. This points to speculative bullish positioning, not a strong, reliable long-term buy signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
6

Positive Catalysts

  • ["MACD histogram is positive and expanding, indicating improving short-term momentum.", "Put-call ratio is extremely low, which reflects bullish options positioning.", "The stock is trading near the pivot level, so a small move could extend toward resistance if momentum continues."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst supporting a move higher.", "Insiders are selling, and selling increased 503.05% over the last month.", "Hedge funds are neutral with no significant accumulation trend.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Estimated near-term stock trend is negative over the next week and month.", "Options liquidity is very thin, making sentiment less trustworthy.", "No recent congress trading data and no influential figure activity reported."]

Financial Performance

No usable latest-quarter financial snapshot was provided, so a quarter-by-quarter growth assessment cannot be completed. The most relevant financial takeaway is that there is no current earnings or revenue update to justify a new long-term entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target trend data was provided. Based on the available Wall Street signals, the pros view is weak bullish sentiment from options activity, while the cons view is stronger: insider selling, neutral hedge fund interest, no recent catalyst, and negative near-term trend expectations.

Wall Street analysts forecast PROK stock price to rise
3 Analyst Rating
Wall Street analysts forecast PROK stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 1.990
sliders
Low
1
Averages
5.33
High
12
Current: 1.990
sliders
Low
1
Averages
5.33
High
12
H.C. Wainwright
Joseph Pantginis
Buy
initiated
$12
AI Analysis
2025-12-16
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$12
AI Analysis
2025-12-16
initiated
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney with a Buy rating and $12 price target. The company is pioneering an approach to postponing progressive kidney dysfunction, the analyst tells investors in a research note. The firm says ProKidney is a late clinical-stage biopharmaceutical company developing rilparencel, an investigational autologous cell therapy targeting patients with moderate to severe chronic kidney disease and type 2 diabetes. It believes rilparencel has the potential to redefine the therapeutic landscape of chronic kidney disease.
UBS
Buy
upgrade
$4 -> $8
2025-07-15
Reason
UBS
Price Target
$4 -> $8
2025-07-15
upgrade
Buy
Reason
UBS raised the firm's price target on ProKidney to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PROK
Unlock Now

People Also Watch